Abstract
Considering the irreversible nature of dementia, lifestyle modification has been recognized as potentially effective preventive strategies. However, whether proteomic signatures of individuals mediate or modifiy the associations between healthy lifestyles and cognitive health remain unclear. Herein, we conducted proteome-wide association analyses and identified 12 plasma proteomic markers that were associated with both overall healthy lifestyle score and incident dementia (Bonferroni corrected P-values <0.05) among 53,014 individuals aged 55 years and older in the UK Biobank. Aggregately, they mediated 17.6% (95% CI, 10.0%, 29.6%) of the lifestyle-dementia association. The associations between overall healthy lifestyle score and two key proteinomic markers (GDF15 and IGFBP3) were further replicated in the Framingham Heart Study Offspring cohort. In the proteome-wide interaction analysis, the lifestyle-dementia association significanly differed by certain proteomic features. Using a machine-learning approach, we developed and tested 8 lifestyle protein stratification scores (LPSSs) to identify pariticipants showing stronger associations between overall or individual healthy lifestyles and dementia. In particular, the LPSS for overall healthy lifestyle (consisting of 25 proteins) identified a population with a substantially stronger lifestyle-dementia association (Harzard Ratio: 0.38, 95%CI: 0.32-0.45) compared with overall population (0.67, 0.60-0.75). Individuals with higher LPSS thus may exibit stronger responses to healthy lifestyle interventions, leading to substantially improved proportions of potentially preventable dementia cases. For example, the population attributable fraction of unhealthy diet increased from 1.63% in the overall population to 29.15% in the targeted population with higher LPSS for healthy diet. Our findings highlighted the key proteomic biomarkers that may serve as intervention intermediate outcomes and inform targeted lifestyle interventions for primary prevention of dementia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Key Research and Development Program of China (No. 2022YFC2010100) and the Zhejiang University Global Partnership Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank was approved by the North West Multi-centre Research Ethics Committee (16/NW/0274). FHS was approved by the Boston Medical Center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 2-5 Revised to be clearer.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
